Abstract
Platelet markers [soluble CD40 ligand (sCD40L) and soluble p selectin (sPselectin)] are associated with platelet activation and cardiovascular events. We sought to investigate the reproducibility of these markers over time and the effect of low-dose aspirin on sCD40L and sPselectin in plasma and serum. Following an overnight fast, 40 healthy volunteers had weekly phlebotomy and were administered aspirin 81 mg/day between weeks 3 and 4. Reproducibility over time was assessed by coefficient of variation (CV) and inter-class correlation coefficient. Correlation between markers was assessed using Pearson r statistic. Difference between levels pre- and post-aspirin was measured with Wilcoxon signed-rank test. Data are presented as median (interquartile range). sCD40L and sPselectin measurements were reproducible over time in plasma and serum (CV < 10 %). Measurement of sCD40L and sPselectin in plasma correlated with levels in serum before aspirin and after aspirin. There was no significant correlation between sCD40L and sPselectin. After 1-week of aspirin 81 mg/day, there was a reduction in sCD40L and sPselectin in serum and plasma, respectively. Soluble CD40L and sPselectin are independent markers that are reproducible over time in both plasma and sera and are reduced by 1-week of low-dose aspirin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blann AD, Lip GY (1997) Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 128:135–138
Sharma G, Berger JS (2011) Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. J Thromb Thrombolysis 32:201–208
Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669–677
Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101:2661–2666
Freedman JE (2003) CD40-CD40L and platelet function: beyond hemostasis. Circ Res 92:944–946
Ridker PM, Buring JE, Rifai N (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103:491–495
Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268
Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS (2014) Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets 25:188–192
Chu SG, Becker RC, Berger PB et al (2010) Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 8:148–156
Thom J, Gilmore G, Yi Q, Hankey GJ, Eikelboom JW (2004) Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2:2067–2069
Mason PJ, Chakrabarti S, Albers AA et al (2005) Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 96:1365–1369
Iversen LH (1997) Pre-analytical variation in the measurements of sensitive markers of coagulation and fibrinolysis: the influence of venipuncture and mixing of blood. Haemostasis 27:119–124
Lee RD, Barcel DA, Williams JC et al (2012) Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 129:80–85
Ahn ER, Lander G, Jy W et al (2004) Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114:143–148
Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U (2006) Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci 111:341–347
Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P (2010) Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem 43:666–670
Ferroni P, Martini F, Riondino S et al (2009) Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim acta; Int J Clin Chem 399:88–91
Chen M, Geng JG (2006) P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Archivum immunologiae et therapiae experimentalis 54:75–84
Santilli F, Basili S, Ferroni P, Davi G (2007) CD40/CD40L system and vascular disease. Intern Emerg Med 2:256–268
Acknowledgments
This study was funded, in part, by a Grant from the Doris Duke Charitable Foundation (2010055). Dr Berger was partially funded by the National Heart and Lung Blood Institute of the National Institutes of Health (RO1HL114978), American Heart Association Clinical Research Program (13CRP14410042) and Doris Duke Charitable Foundation (2010055).
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Valdes, V., Nardi, M.A., Elbaum, L. et al. Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand. J Thromb Thrombolysis 40, 83–87 (2015). https://doi.org/10.1007/s11239-015-1179-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-015-1179-5